1442371-89-2

Upstream product

• 110-91-8 morpholine 
• 1442371-84-7 10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 1387627-09-9 1-(2-chloro-10H-phenothiazin-10-yl)-4-(2-(4-methoxyphenyl)-2H-tetrazol-5-yl)butan-2-ol 

Downstream Products

• 1442371-76-7 4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]-1-(2-morpholin-4-yl-5-oxido-10H-phenothiazin-10-yl)butan-2-ol 
• 1442371-94-9 4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]-1-[5-oxido-2-(4-oxidomorpholin-4-yl)-10H-phenothiazin-10-yl]butan-2-ol 

Relevant academic research and scientific papers

Synthesis and pharmacological investigation of new N-hydroxyalkyl-2- aminophenothiazines exhibiting marked MDR inhibitory effect

Novel N-hydroxyalkyl-2-aminophenothiazines implying a tetrazole moiety at the alkyl chain have been synthesized by hydroboration-oxidation of dienes followed by Buchwald-Hartwig cross-coupling reaction. Also, some sulfoxide and sulfone derivatives have been prepared by selective oxidations. MDR inhibition studies on rat hepatocyte cell culture revealed that some derivatives exhibit marked biological efficacy exceeding that of the standard verapamil (e.g., 3h, 4h, 16). Selected derivatives were subjected to chemical resolution to provide both enantiomers which were shown of similar activity on P-gp interaction measurements. The new compounds exhibited no toxicity.